Argos Therapeutics to Present at Regenerative Medicine and Cancer Immunotherapy Meetings

Company Updates to be Presented at Second Annual Regen Med Investor Day and 4th Annual Cancer Immunotherapy: a Long Awaited Reality Conference

        Print
| Source: Argos Therapeutics, Inc.

DURHAM, N.C., March 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will be presenting at the Second Annual Regen Med Investor Day hosted by the Alliance for Regenerative Medicine on March 26, and the 4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference presented by Maidstone Life Sciences on March 27. Frederick Miesowicz, Ph.D., chief operating officer of Argos, will be presenting on behalf of the company at both events and will be providing an update on progress related to the development of AGS-003, Argos's fully personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma, and upcoming milestones.

Event: Second Annual Regen Med Investor Day
Date: Wednesday, March 26, 2014
Time: 4:15 p.m. ET
Location: The Metropolitan Club, New York City
   
Event: 4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference
Date: Thursday, March 27, 2014
Time: 9:30 a.m. and 11:45 a.m. ET 
Location:  The New York Academy of Medicine, New York City

At the 4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference, Dr. Miesowicz's update presentation will begin at 9:30 a.m. He will also participate in a panel discussion entitled Autologous Immunotherapies at 11:45 a.m.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.  Argos´ most advanced product candidate, AGS-003, is in a pivotal Phase 3 trial for the treatment of mRCC, and the company plans to have data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.  

Media:
Andrea Coan
Berry & Company Public Relations

(212) 253-8881

Investors:
Angeli Kolhatkar
Burns McClellan

(212) 213-0006